Garau J
Department of Medicine, Hospital Mutua de Terrassa, Plaza Dr Robert 5, 08221 Terrassa, Barcelona, Spain.
Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):83-99. doi: 10.1007/s10096-005-1287-9.
Community-acquired pneumonia (CAP) is a common illness associated with high rates of morbidity and mortality worldwide. The beta-lactam antibacterial agents have been the mainstay of therapy for CAP for over four decades and remain as first-line therapy. However, the impact of the substantial prevalence of resistance seen among the common respiratory pathogens, particularly penicillin and macrolide resistance among Streptococcus pneumoniae, is now an area for concern. CAP treatment guidelines often recommend the use of a macrolide or fluoroquinolone in conjunction with, or as an alternative to, beta-lactam agents, but whether this is necessary is uncertain. This review outlines the historical use of beta-lactam antibacterial agents in the treatment of CAP along with their ongoing therapeutic utility.
社区获得性肺炎（CAP）是一种常见疾病，在全球范围内发病率和死亡率都很高。四十多年来，β-内酰胺类抗菌药物一直是CAP治疗的主要药物，至今仍是一线治疗药物。然而，常见呼吸道病原体中耐药性普遍存在的影响，尤其是肺炎链球菌对青霉素和大环内酯类药物的耐药性，现在已成为一个令人担忧的问题。CAP治疗指南通常建议将大环内酯类药物或氟喹诺酮类药物与β-内酰胺类药物联合使用，或作为β-内酰胺类药物的替代品，但这样做是否必要尚不确定。本综述概述了β-内酰胺类抗菌药物在CAP治疗中的历史应用及其当前的治疗效用。
